Frontiers Clinical and Translational Science Institute at the University of Kansas

堪萨斯大学前沿临床与转化科学研究所

• 批准号: 10674055
• 负责人: Mario Castro
• 金额: $ 381.79万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-07 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10674055
• 关键词: Acceleration; Address; Adopted; AstraZeneca COVID-19 vaccine; Biological Markers; COVID testing; COVID-19; COVID-19 pandemic; COVID-19 pathogenesis; COVID-19 therapeutics; COVID-19 treatment; COVID-19 vaccine evaluation; Career Mobility; Child; Cities; Clinical Informatics; Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Unit; Collaborations; Communication; Communities; Conduct Clinical Trials; County; Creativeness; Data; Data Set; Decision Making; Development; Diagnostic; Discipline; Disease; Diverse Workforce; Ensure; Environment; Equity; Exclusion; Fostering; Funding; Genomic medicine; Genomics; Goals; Grant; Health; Health Priorities; Health system; Healthcare; Healthcare Systems; Hospitals; Human; Individual; Informatics; Infrastructure; Institution; Intervention; Intervention Trial; Investments; Kansas; Knowledge; Latinx; Leadership; Learning; Longevity; Maps; Measures; Medical center; Methods; Midwestern United States; Mission; Missouri; Patients; Population; Population Heterogeneity; Public Health; RADx; Rare Diseases; Research; Research Design; Research Methodology; Research Personnel; Resources; Rural; Rural Community; SARS-CoV-2 infection; Safety; Science; Structure; TNFSF15 gene; Therapeutic Intervention; Training; Translating; Translational Research; Underrepresented Populations; Underserved Population; Universities; Vision; Work; Workforce Development; career development; catalyst; collaborative approach; community organizations; coronavirus disease; design; experience; frontier; health care quality; health disparity; health equity; human subject; improved; innovation; multi-component intervention; nano; novel; patient advocacy group; point of care; preventive intervention; programs; recruit; response; symposium; tool; vaccine trial

Contact PD/PI: Castro, Mario OVERALL PROJECT SUMMARY/ABSTRACT The Frontiers Clinical and Translational Science Institute at the University of Kansas (Frontiers) has been a catalyst for clinical and translational research (CTR) across the Kansas City region. The vision of Frontiers 3.0 is to transform the way we do CTR and ensure that research is rapidly translated to the point of care in a way that improves health for underserved and excluded populations, especially those in rural communities. To do so, we have expanded Frontiers 3.0 partners to include multiple academic institutions, healthcare systems, and community organizations and patient advocacy groups across Kansas and western Missouri. Our new shared leadership structure balances power across institutions. The overall aims of Frontiers are: Aim 1. Train a diverse workforce that leverages multiple disciplines, frameworks and approaches to stimulate creative, responsive and impactful T1-T4 clinical and translational research. Frontiers cores and its KL2 and TL1 programs provide high quality training, assistance in research design and implementation, guidance in applying for grants, and support for career advancement for all levels translational research trainees. In Frontiers 3.0 we emphasize identifying and supporting investigators from underrepresented groups and those with a research focus on underserved and excluded populations. Aim 2. Collaborate and engage with underserved and excluded communities to ensure that clinical and translational research is responsive to their priorities and achieves greater health equity. Frontiers 3.0 hosts Design Studios, Fieldwork Nano-experiences, Story-telling sessions, Community Co- Investigator Human Subjects Training and Conferences to support collaborations between researchers and patients, communities, and stakeholders. New advisory groups of community partners and community- engaged researchers provide guidance at all levels of Frontiers decisionmaking. We expand our novel efforts to understand and address COVID-19 across the lifespan and among underserved and excluded groups. Aim 3. Drive innovative, quality, and efficient clinical and translational research across the lifespan that harnesses novel informatics, genomics, team science and implementation methods to enhance delivery of high-quality healthcare in the region. Frontiers reduces barriers to entering CTR by providing unparalleled comprehensive support that minimizes regulatory burden and expedites research. New cores provide entre to tools and data for pursuing genomic medicine and help investigators access and analyse rich datasets available via clinical informatics. New leadership in Team Science will map investigator networks, identify gaps, and introduce individual and team- level interventions to help investigators build and maintain effective teams. Frontiers will accelerate CTR in the Midwest and build a workforce that attends to health priorities for the rural, underserved, and excluded. Our discoveries and new tools will contribute to knowledge for the nation. Project Summary/Abstract Page 302 Contact PD/PI: Castro, Mario OVERALL NARRATIVE The Frontiers Clinical and Translational Sciences Institute at the University of Kansas is a regional initiative involving academic institutions, healthcare systems and community organizations that addresses the clinical and translational research needs of Kansas and western Missouri. Frontiers supports high quality translational science and clinical research locally, regionally and nationally. It fosters innovation in research methods, training, and career development of investigators committed to improving health and achieving health equity across the lifespan, with a focus on underserved and excluded populations.

联系PD/PI：Castro，Mario 总体项目摘要/摘要 堪萨斯大学（Frontiers）的边境临床和转化科学学院一直是 堪萨斯城地区的临床和转化研究催化剂（CTR）。边境的愿景3.0 是为了改变我们进行CTR的方式，并确保以某种方式将研究迅速转化为护理点 这可以改善服务不足和被排除在外的人口，尤其是农村社区的人口。做 因此，我们已经扩大了Frontiers 3.0合作伙伴，包括多个学术机构，医疗保健系统和 堪萨斯州和密苏里州西部的社区组织和患者倡导团体。我们的新共享 领导力结构平衡了跨机构的权力。边境的总体目标是： 目标1。培训一支多样化的劳动力，该劳动力利用了多个学科，框架和方法 刺激创造性，响应和有影响力的T1-T4临床和翻译研究。 边境核心及其KL2和TL1计划提供高质量的培训，研究设计的帮助和 实施，申请赠款的指导以及对各个级别的职业发展的支持 研究学员。在边境3.0中，我们强调从 代表性不足的群体和研究的群体集中于服务不足和被排除在外的人群。 目标2。协作并与服务不足和排除的社区互动，以确保临床和 翻译研究对其优先事项有反应，并实现了更大的健康公平。 Frontiers 3.0主持设计工作室，现场工作纳米体验，讲故事会议，社区共同 研究人员人类受试者培训和会议，以支持研究人员与 患者，社区和利益相关者。社区合作伙伴和社区的新咨询小组 - 敬业的研究人员在各个方面的决策层面提供指导。我们扩大了新颖的努力 在整个生命周期内以及服务不足和被排除的群体中了解和解决Covid-19。 目标3。在整个生命周期中推动创新，质量和有效的临床和转化研究 利用新颖的信息学，基因组学，团队科学和实施方法来增强 在该地区提供高质量的医疗保健。 边境通过提供无与伦比的全面支持来减少进入CTR的障碍 监管负担和加急研究。新核心提供了追求基因组的工具和数据 医学并帮助研究人员访问和分析通过临床信息学获得的丰富数据集。新的 团队科学领域的领导将绘制研究人员网络，识别差距，并介绍个人和团队 - 水平干预措施，以帮助调查人员建立和维护有效的团队。 边境将在中西部加速CTR，并建立一个劳动力，这是农村地区的健康优先事项 服务不足，被排除在外。我们的发现和新工具将为国家的知识做出贡献。 项目摘要/摘要页面302 联系PD/PI：Castro，Mario 总体叙述 堪萨斯大学的边境临床和转化科学研究所是 涉及学术机构，医疗保健系统和社区的区域倡议 满足堪萨斯州临床和转化研究需求的组织 密苏里州西部。边境支持高质量的转化科学和临床研究 在本地，地区和全国范围内。它促进了研究方法，培训和职业的创新 发展致力于改善健康和实现健康平等的调查人员 寿命，重点是服务不足和被排除在外的人群。